Table 2.
ePRO Scores over 6 cycles of induction treatment regimen.
| ePRO EORTC | Domains (0–100) | Overall cohorts (A + B) |
Cohort A (age <65 years) |
Cohort B (age ≥65 years) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean baseline scores (SD) | Trend (95% CI) (score/cycle) | Net average change (95% CI) (score after 6 cycles) | p-value | Mean baseline scores (SD) | Trend (95% CI) (score/cycle) | Net average change (95% CI) (score after 6 cycles) | p-value | Mean baseline scores (SD) | Trend (95% CI) (score/cycle) | Net average change (95% CI) (score after 6 cycles) | p-value | ||
| QLQ30 | Physical function | 78 (23) | +2.1 (1.2–3.0) | +12.6 (7.2–18) | p < 0.0001 | 85 (20) | +1.9 (0.7–3.9) | +11.4 (4.2–18.6) | p = 0.0032 | 72 (24) | +2.4 (1.1–3.7) | +14.4 (6.4–22.4) | p = 0.0032 |
| QLQ30 | Global health status/QoL | 66 (24) | +1.7 (0.3–3.1) | +10.2 (1.9–18.6) | p = 0.016 | 79 (20) | +0.5 (−1.2 to 2.2) | +3.0 (−7.2 to 13.2) | p = 0.59 | 56 (22) | +3.0 (0.8–5.1) | +18 (4.8–30.6) | p = 0.0071 |
| MY20 | Disease burden symptoms | 27 (20) | −1.6 (−2.6 to −0.6) | −9.6 (−3.8 to −15.4) | p = 0.0013 | 23 (11) | −1.4 (−2.6 to −0.2) | −8.4 (−15.6 to −1.2) | p = 0.02 | 30 (24) | −1.7 (−3.2 to −0.2) | −10.2 (−19.2 to −1.2) | p = 0.03 |
| MY20 | Future perspective | 48 (23) | −2.8 (−3.8 to −1.8) | −16.8 (−23.0 to −10.6) | p < 0.0001 | 48 (25) | −3.4 (−4.8 to −2.1) | −20.4 (−28.5 to −12.3) | p < 0.0001 | 49 (23) | −2.1 (−3.7 to −0.6) | −12.8 (−22.1 to −3.6) | p = 0.0066 |
| MY20 | Self-Body image | 20 (24) | −0.6 (−2.3 to 1.1) | −3.6 (−13.8 to 6.7) | p = 0.5 | 15 (22) | −1.3 (−3.5 to 0.9) | −7.8 (−21 to 5.4) | p = 0.22 | 23 (26) | 0.1 (−2.5 to 2.8) | +0.6 (−15 to 16.8) | p = 0.91 |